{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:17:43Z","timestamp":1760426263067,"version":"3.41.2"},"reference-count":36,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Izuforant is a selective, and potent histamine H4 receptor (H4R) antagonist developed to treat atopic dermatitis (AD). There is an unmet medical need for therapeutic agents to control inflammation and pruritus. Izuforant is a strong candidate for this task based on the findings of non\u2010clinical studies showing that inhibition of the histamine\u2010mediated signaling pathway via H4R by izuforant results in decreased pruritus and inflammation. This study aimed to evaluate the clinical pharmacokinetic (PK) and pharmacodynamic (PD) profiles of izuforant. Dose\u2010block\u2010randomized, double\u2010blind, placebo\u2010controlled, single\u2010 and multiple ascending dose studies were conducted in 64 healthy volunteers. For the single ascending dose (SAD) study, 10\u2013600\u2009mg izuforant was administered to the designated groups. For the multiple ascending dose (MAD) study, 100\u2013400\u2009mg izuforant was administered to three groups. The clinical pharmacokinetic (PK) profile of izuforant was evaluated using plasma and urine concentrations. Blood sampling for the PD assay, which measured imetit\u2010induced eosinophil shape changes (ESC), was also conducted. A one\u2010compartment PK model described the distribution and elimination profiles of izuforant. An imetit\u2010induced ESC inhibition test was established and validated for PD evaluation as a measure of the H4R antagonistic effect. ESC inhibition was observed even at doses as low as 10\u2009mg; however, this inhibition became stronger and lasted longer as the dose increased. All izuforant doses were well tolerated, and no discontinuations due to adverse events (AE) or deaths were reported.<\/jats:p>","DOI":"10.1111\/cts.70032","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T16:39:19Z","timestamp":1729528759000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8655-4076","authenticated-orcid":false,"given":"Byung Hak","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Severance Hospital Yonsei University College of Medicine  Seoul South Korea"},{"name":"Department of Pharmaceutical Medicine and Regulatory Science, Colleges of Medicine and Pharmacy Yonsei University  Incheon South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7490-0085","authenticated-orcid":false,"given":"Taegon","family":"Hong","sequence":"additional","affiliation":[{"name":"Clinical Trial Center Seoul Bumin Hospital  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-1484","authenticated-orcid":false,"given":"Byung Won","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Severance Hospital Yonsei University College of Medicine  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-1108","authenticated-orcid":false,"given":"Choon Ok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Severance Hospital Yonsei University College of Medicine  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7925-194X","authenticated-orcid":false,"given":"Dasohm","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Severance Hospital Yonsei University College of Medicine  Seoul South Korea"},{"name":"Department of Pharmaceutical Medicine and Regulatory Science, Colleges of Medicine and Pharmacy Yonsei University  Incheon South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-6218","authenticated-orcid":false,"given":"Youn Nam","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Severance Hospital Yonsei University College of Medicine  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4395-9938","authenticated-orcid":false,"given":"Min Soo","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Severance Hospital Yonsei University College of Medicine  Seoul South Korea"},{"name":"Department of Pharmaceutical Medicine and Regulatory Science, Colleges of Medicine and Pharmacy Yonsei University  Incheon South Korea"},{"name":"Department of Pediatrics Yonsei University College of Medicine  Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01873"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2007.139352"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00227.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2006.06.005"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.3.420"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00961.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.12.8081"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.4008"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006480200"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2012.10.030"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046581"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.087965"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705729"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.01670"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3619"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1950"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.01995.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2012.20.6.506"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0b013e3282fdf6c5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.034"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12193-9"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.193674"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e3283551da5"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.01.054"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02571.x"},{"volume-title":"Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","year":"2005","author":"FDA US","key":"e_1_2_10_27_1"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026451721686"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20514"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.07.125"},{"issue":"1","key":"e_1_2_10_31_1","first-page":"1013","article-title":"Pharmacology and clinical activity of toreforant, a histamine H4 receptor antagonist","volume":"2","author":"Thurmond RL","year":"2017","journal-title":"Ann Pharmacol Pharmaceut"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.211714"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705530"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-019-01218-y"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.07.047"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12726"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae038"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T13:34:37Z","timestamp":1729863277000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/cts.70032"],"URL":"https:\/\/doi.org\/10.1111\/cts.70032","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"type":"print","value":"1752-8054"},{"type":"electronic","value":"1752-8062"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70032"}}